&Partners’s Genmab GMAB Stock Holding History

&Partners’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,831	Closed	-$272K	–	2434
2025 Q4	$272K	Buy	+8,831	New	+$275K	﹤0.01%	1971
2025 Q1	–	Sell	-12,482	Closed	-$268K	–	1780
2024 Q4	$268K	Buy	12,482 +564	+5%	+$12.4K	﹤0.01%	1394
2024 Q3	$290K	Buy	+11,918	New	+$319K	0.01%	1116

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

&Partners's GMAB Position: Q1 2026 in Review

&Partners sold out of Genmab (GMAB) in Q1 2026, closing a stake of 8,831 shares — an estimated $272K sold.

&Partners first reported a position in GMAB in Q3 2024 and held it in 3 quarters. The position peaked at $290K in Q3 2024. 275 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

&Partners reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
&Partners sold 8,831 Genmab shares in Q1 2026, an estimated $272K.
&Partners first reported a position in Genmab in Q3 2024 and held it in 3 quarters.
&Partners's Genmab position peaked at $290K in Q3 2024.
275 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.